Comparative Efficacy of Laser Systems and Fluoride in Managing Dentinal Hypersensitivity: RCT (DHLT)
Comparative Efficacy of Erbium and Diode Laser Systems Alone or Combined With Fluoride-Based Desensitizing Agent in the Management of Dentinal Hypersensitivity: A Randomized Controlled Clinical Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria
- Adults aged 18-45 years
- Both sexes eligible
- Good general health status
- At least one tooth with cervical dentin hypersensitivity (CDH)
- Visual Analogue Scale (VAS) pain score ≥ 4 on evaporative stimulus test using dental syringe air jet
- Willing to participate and provide informed consent
Exclusion Criteria
- Active carious lesions or defective restorations requiring treatment
- Loss of dental tissue requiring restorative treatment
- Previous professional desensitizing treatment within 6 months prior to recruitment
- Use of desensitizing toothpastes within 3 months prior to study
- Current use of anti-inflammatory drugs or analgesics at time of recruitment
- Pregnant or breastfeeding women
- Inability to comply with study protocol or follow-up requirements
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Erbium Laser
Erbium:YAG laser (2940 nm) treatment alone using thermal ablation to seal dentinal tubules and reduce hypersensitivity.
|
Non-ionizing radiation or more accurately as optical energy devices, not ionizing radiation.
Biological Intervention
|
|
Experimental: Diode Laser
Diode laser (650 nm) photobiomodulation therapy alone targeting neural modulation to reduce pain transmission.
|
Biological Intervention
The lasers emit light energy in the infrared and visible spectrum, which is fundamentally different from ionizing radiation (like X-rays or gamma rays) that can damage DNA.
Dental lasers work through photobiomodulation and thermal effects, not through radiation exposure.
|
|
Experimental: Combination Therapy
Diode laser (650 nm) followed immediately by fluoride varnish application combining neural modulation with tubule occlusion.
|
Non-ionizing radiation or more accurately as optical energy devices, not ionizing radiation.
Biological Intervention
The lasers emit light energy in the infrared and visible spectrum, which is fundamentally different from ionizing radiation (like X-rays or gamma rays) that can damage DNA.
Dental lasers work through photobiomodulation and thermal effects, not through radiation exposure.
|
|
Active Comparator: Fluoride Control
5% sodium fluoride varnish alone serving as active control, promoting remineralization and tubule occlusion through standard treatment.
|
Non-ionizing radiation or more accurately as optical energy devices, not ionizing radiation.
The lasers emit light energy in the infrared and visible spectrum, which is fundamentally different from ionizing radiation (like X-rays or gamma rays) that can damage DNA.
Dental lasers work through photobiomodulation and thermal effects, not through radiation exposure.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Dentinal Hypersensitivity Assessment
Time Frame: at baseline, 1 week, 4 weeks, and 6 months post-treatment
|
Dentinal Hypersensitivity Assessment Using Visual Analogue Scale
|
at baseline, 1 week, 4 weeks, and 6 months post-treatment
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Patient Satisfaction
Time Frame: at baseline, 1 week, 4 weeks, and 6 months post-treatment
|
The secondary outcome measures patient satisfaction with treatment using a categorical Yes/No assessment.
Participants report their overall satisfaction with the assigned intervention based on perceived pain relief.
|
at baseline, 1 week, 4 weeks, and 6 months post-treatment
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CairoU-Laser Hypersensitivity
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.